European Stroke Prevention Study "ESPS-2"


Phase N/A Results

Trial Description

To study the effectiveness of dipyridamole and low-dose aspirin, taken alone or in combination, for secondary stroke prevention.


Trial Design

Randomized, double-blind, placebo-controlled, trial of 6602 patients at 59 centers.

Patient Involvement

Patients were randomized to participate in 1 of 4 groups. 1) aspirin (25 mg twice daily) 2) modified-release dipyridamole (200 mg twice daily) 3) aspirin (25 mg twice daily) and modified-release dipyridamole (200 mg twice daily) 4) placebo.


Type Measure Time Frame Safety Issue
Primary Stroke, death, and stroke and/or death as determined in follow-up visits 1 month after inclusion and thereafter, every 3 months for 2 years.
Secondary TIA, myocardial infarction, ischemic events and other vascular events.